Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. / Andersson, Charlotte; Gislason, Gunnar H; Jørgensen, Casper H; Hansen, Peter R; Vaag, Allan; Sørensen, Rikke; Mérie, Charlotte; Olesen, Jonas B; Weeke, Peter; Schmiegelow, Michelle; Norgaard, Mette L; Køber, Lars; Torp-Pedersen, Christian.
In: Diabetes Research and Clinical Practice, Vol. 94, No. 1, 2011, p. 119-25.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure
AU - Andersson, Charlotte
AU - Gislason, Gunnar H
AU - Jørgensen, Casper H
AU - Hansen, Peter R
AU - Vaag, Allan
AU - Sørensen, Rikke
AU - Mérie, Charlotte
AU - Olesen, Jonas B
AU - Weeke, Peter
AU - Schmiegelow, Michelle
AU - Norgaard, Mette L
AU - Køber, Lars
AU - Torp-Pedersen, Christian
N1 - Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
PY - 2011
Y1 - 2011
N2 - The aim was to investigate the outcomes of individual sulfonylureas in patients with heart failure (HF). Methods All patients hospitalized with HF for the first time in 1997–2006, alive 30 days after discharge, and who received anti-diabetic monotherapy with glimepiride (n = 1097), glibenclamide (glyburide) (n = 1031), glipizide (n = 557), gliclazide (n = 251), or tolbutamide (n = 541) were identified from nationwide registers. Risk of all-cause mortality was assessed by multivariable Cox regression models. Results Over the median observational time of 744 (Inter Quartile Range 268–1451) days, 2242 patients (64%) died. The analysis demonstrated similar hazard ratio (HR) for mortality for treatment with glimepiride (1.10 [95% confidence interval 0.92–1.33]), glibenclamide (1.12 [0.93–1.34]), glipizide (1.14 [0.93–1.38]), tolbutamide (1.04 [0.85–1.26]), and gliclazide (reference). Grouped according to pancreatic specificity, i.e., with tolbutamide, glipizide, and gliclazide as specific, and glibenclamide, and glimepiride as non-specific agents, no differential prognosis was found between the two groups (HR 1.04 [0.96–1.14], for non-specific, compared to pancreas specific agents). The prognosis was not dependent on prior acute myocardial infarction or ischemic heart disease (p for interactions >0.3). Conclusions In current clinical practice, it is unlikely that there are considerable differences in risk of mortality associated with individual sulfonylureas in patients with heart failure.
AB - The aim was to investigate the outcomes of individual sulfonylureas in patients with heart failure (HF). Methods All patients hospitalized with HF for the first time in 1997–2006, alive 30 days after discharge, and who received anti-diabetic monotherapy with glimepiride (n = 1097), glibenclamide (glyburide) (n = 1031), glipizide (n = 557), gliclazide (n = 251), or tolbutamide (n = 541) were identified from nationwide registers. Risk of all-cause mortality was assessed by multivariable Cox regression models. Results Over the median observational time of 744 (Inter Quartile Range 268–1451) days, 2242 patients (64%) died. The analysis demonstrated similar hazard ratio (HR) for mortality for treatment with glimepiride (1.10 [95% confidence interval 0.92–1.33]), glibenclamide (1.12 [0.93–1.34]), glipizide (1.14 [0.93–1.38]), tolbutamide (1.04 [0.85–1.26]), and gliclazide (reference). Grouped according to pancreatic specificity, i.e., with tolbutamide, glipizide, and gliclazide as specific, and glibenclamide, and glimepiride as non-specific agents, no differential prognosis was found between the two groups (HR 1.04 [0.96–1.14], for non-specific, compared to pancreas specific agents). The prognosis was not dependent on prior acute myocardial infarction or ischemic heart disease (p for interactions >0.3). Conclusions In current clinical practice, it is unlikely that there are considerable differences in risk of mortality associated with individual sulfonylureas in patients with heart failure.
U2 - 10.1016/j.diabres.2011.07.011
DO - 10.1016/j.diabres.2011.07.011
M3 - Journal article
C2 - 21831467
VL - 94
SP - 119
EP - 125
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
SN - 0168-8227
IS - 1
ER -
ID: 40155616